• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

测定诺如病毒的 50%人体感染剂量。

Determination of the 50% human infectious dose for Norwalk virus.

机构信息

Department of Medicine.

出版信息

J Infect Dis. 2014 Apr 1;209(7):1016-22. doi: 10.1093/infdis/jit620. Epub 2013 Nov 18.

DOI:10.1093/infdis/jit620
PMID:24253285
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3952671/
Abstract

BACKGROUND

Noroviruses are the most common cause of gastroenteritis in the United States. An understanding of the infectious dose of these viruses is important for risk assessment studies.

METHODS

Healthy adults were enrolled in a randomized, double-blind, placebo-controlled evaluation of different dosages of Norwalk virus. Eligible subjects were monitored for clinical gastroenteritis, and infection status was determined. The presence of virus in vomitus was also assessed.

RESULTS

Fifty-seven persons were enrolled; 8 received placebo and an additional 8 persons were considered to be nonsusceptible on the basis of being secretor negative. Twenty-one persons were infected (all blood group O or A), and 67% of those infected developed viral gastroenteritis. The 50% human infectious dose was calculated to be 3.3 reverse transcription polymerase chain reaction units (approximately 1320 genomic equivalents [gEq]) for secretor-positive blood group O or A persons and 7.0 (approximately 2800 gEq) for all secretor-positive persons. The time of illness onset was inversely correlated with inoculum dose. The maximal concentration of virus shedding was higher for persons with gastroenteritis. Norwalk virus was identified in 15 of 27 (56%) vomitus samples at a median concentration of 41 000 gEq/mL.

CONCLUSIONS

The 50% human infectious dose measured is higher than previous estimates and similar to that of other RNA viruses. Clinical Trials Registration NCT00138476.

摘要

背景

诺如病毒是美国最常见的胃肠道疾病病原体。了解此类病毒的感染剂量对于风险评估研究至关重要。

方法

健康成年人参与了一项随机、双盲、安慰剂对照的诺如病毒不同剂量评估研究。合格的研究对象接受临床胃肠炎监测,并确定其感染状态。同时还评估了呕吐物中病毒的存在情况。

结果

共有 57 人入组;8 人接受安慰剂,另外 8 人因非分泌型而被认为不敏感。21 人感染(均为 O 型或 A 型血),67%的感染者发生病毒性胃肠炎。50%人体感染剂量计算为分泌型 O 型或 A 型血者为 3.3 个逆转录聚合酶链反应单位(约 1320 基因组当量[gEq]),所有分泌型阳性者为 7.0(约 2800 gEq)。发病时间与接种剂量呈负相关。有胃肠道症状者的病毒排出量最高。在 27 份(56%)呕吐物样本中检测到 15 份(56%)诺如病毒,中位数浓度为 41000 gEq/mL。

结论

测量得到的 50%人体感染剂量高于既往估计值,与其他 RNA 病毒相似。

临床试验注册

NCT00138476。

相似文献

1
Determination of the 50% human infectious dose for Norwalk virus.测定诺如病毒的 50%人体感染剂量。
J Infect Dis. 2014 Apr 1;209(7):1016-22. doi: 10.1093/infdis/jit620. Epub 2013 Nov 18.
2
Norwalk virus shedding after experimental human infection.人类实验性感染后诺如病毒的排泄情况。
Emerg Infect Dis. 2008 Oct;14(10):1553-7. doi: 10.3201/eid1410.080117.
3
Disease course and viral shedding in experimental Norwalk virus and Snow Mountain virus infection.实验性诺如病毒和雪山病毒感染的疾病过程和病毒脱落。
J Med Virol. 2014 Dec;86(12):2055-64. doi: 10.1002/jmv.23905. Epub 2014 Feb 14.
4
Norwalk virus: how infectious is it?诺如病毒:它的传染性有多强?
J Med Virol. 2008 Aug;80(8):1468-76. doi: 10.1002/jmv.21237.
5
High level excretion of Norwalk-like virus following resolution of clinical illness.临床疾病痊愈后诺如病毒样病毒的高水平排泄。
Pathology. 2001 Feb;33(1):50-2.
6
Less severe clinical symptoms of Norwalk virus 8fIIb inoculum compared to its precursor 8fIIa from human challenge studies.人体挑战研究中,诺如病毒 8fIIb 接种物的临床症状较其前体 8fIIa 有所减轻。
J Med Virol. 2021 Jun;93(6):3557-3563. doi: 10.1002/jmv.26578. Epub 2020 Oct 30.
7
Norovirus vaccine against experimental human Norwalk Virus illness.诺如病毒疫苗对实验性人类诺如病毒病的作用。
N Engl J Med. 2011 Dec 8;365(23):2178-87. doi: 10.1056/NEJMoa1101245.
8
Serological correlate of protection against norovirus-induced gastroenteritis.诺如病毒胃肠炎血清保护相关性。
J Infect Dis. 2010 Oct 15;202(8):1212-8. doi: 10.1086/656364.
9
Production and Clinical Evaluation of Norwalk GI.1 Virus Lot 001-09NV in Norovirus Vaccine Development.诺如病毒疫苗研发中诺瓦克 GI.1 病毒 001-09NV 批的生产和临床评估。
J Infect Dis. 2020 Mar 2;221(6):919-926. doi: 10.1093/infdis/jiz540.
10
Evaluation of nine sets of PCR primers in the RNA dependent RNA polymerase region for detection and differentiation of members of the family Caliciviridae, Norwalk virus and Sapporo virus.评价九组用于检测和区分杯状病毒科成员、诺如病毒和札幌病毒的RNA依赖RNA聚合酶区域的PCR引物。
Microbiol Immunol. 2000;44(5):411-9. doi: 10.1111/j.1348-0421.2000.tb02515.x.

引用本文的文献

1
The burden and etiologies of diarrhea in Asia and its countries from 1990 to 2021 and the forecast to 2040: analyses informed by the global burden of disease study 2021.1990年至2021年亚洲及其各国腹泻的负担、病因及到2040年的预测:基于2021年全球疾病负担研究的分析
Front Public Health. 2025 Aug 6;13:1651315. doi: 10.3389/fpubh.2025.1651315. eCollection 2025.
2
Investigation of a norovirus outbreak among hospital staff in Zhejiang, China: tracing the source to contaminated "red bean cake".中国浙江医院工作人员中诺如病毒暴发的调查:溯源至受污染的“红豆糕”
Front Public Health. 2025 Jul 24;13:1631091. doi: 10.3389/fpubh.2025.1631091. eCollection 2025.
3
Complete genomic characterization of global pathogens respiratory syntical virus and human norovirus using probe based capture enrichment.利用基于探针的捕获富集技术对全球病原体呼吸道合胞病毒和人诺如病毒进行全基因组特征分析。
Sci Rep. 2025 Jul 1;15(1):20526. doi: 10.1038/s41598-025-03398-6.
4
Nucleic Acid Aptamers for Human Norovirus GII.4 and GII.17 Virus-Like Particles (VLPs) Exhibit Specific Binding and Inhibit VLPs from Entering Cells.用于人诺如病毒GII.4和GII.17病毒样颗粒(VLPs)的核酸适配体表现出特异性结合并抑制VLPs进入细胞。
Int J Nanomedicine. 2025 Feb 11;20:1789-1805. doi: 10.2147/IJN.S495399. eCollection 2025.
5
Norovirus replication, host interactions and vaccine advances.诺如病毒的复制、宿主相互作用及疫苗进展。
Nat Rev Microbiol. 2025 Jun;23(6):385-401. doi: 10.1038/s41579-024-01144-9. Epub 2025 Jan 17.
6
H and B Blood Antigens Are Essential for In Vitro Replication of GII.2 Human Norovirus.H和B血型抗原对于GII.2型人诺如病毒的体外复制至关重要。
Open Forum Infect Dis. 2024 Dec 18;12(1):ofae714. doi: 10.1093/ofid/ofae714. eCollection 2025 Jan.
7
Lack of Detection of Norwalk Virus in Saliva Samples From a Controlled Human Infection Model.在一项人体感染对照模型的唾液样本中未检测到诺如病毒。
Open Forum Infect Dis. 2024 Nov 4;11(11):ofae652. doi: 10.1093/ofid/ofae652. eCollection 2024 Nov.
8
Complete Genomic Characterization of Global Pathogens, Respiratory Syncytial Virus (RSV), and Human Norovirus (HuNoV) Using Probe-based Capture Enrichment.利用基于探针的捕获富集技术对全球病原体呼吸道合胞病毒(RSV)和人诺如病毒(HuNoV)进行全基因组特征分析。
bioRxiv. 2024 Sep 16:2024.09.16.613242. doi: 10.1101/2024.09.16.613242.
9
Virus Shedding and Diarrhea: A Review of Human Norovirus Genogroup II Infection in Gnotobiotic Pigs.病毒脱落与腹泻:人诺如病毒基因Ⅱ组感染无菌猪的研究综述。
Viruses. 2024 Sep 7;16(9):1432. doi: 10.3390/v16091432.
10
Prevalence and associated factors of norovirus infections among patients with diarrhea in the Amhara national regional state, Ethiopia.在埃塞俄比亚阿姆哈拉州,腹泻患者中诺如病毒感染的流行情况及相关因素。
BMC Infect Dis. 2024 Sep 27;24(1):1053. doi: 10.1186/s12879-024-09988-5.

本文引用的文献

1
Norovirus disease in the United States.美国诺如病毒病。
Emerg Infect Dis. 2013 Aug;19(8):1198-205. doi: 10.3201/eid1908.130465.
2
Burden of norovirus gastroenteritis in the ambulatory setting--United States, 2001-2009.在门诊环境中诺如病毒胃肠炎的负担-美国,2001-2009 年。
J Infect Dis. 2013 Apr;207(7):1058-65. doi: 10.1093/infdis/jis942. Epub 2013 Jan 8.
3
Antibody responses to norovirus genogroup GI.1 and GII.4 proteases in volunteers administered Norwalk virus.接种诺沃克病毒的志愿者对诺如病毒GI.1和GII.4蛋白酶的抗体反应。
Clin Vaccine Immunol. 2012 Dec;19(12):1980-3. doi: 10.1128/CVI.00411-12. Epub 2012 Oct 3.
4
Predicting susceptibility to norovirus GII.4 by use of a challenge model involving humans.利用涉及人类的挑战模型预测诺如病毒 GII.4 的易感性。
J Infect Dis. 2012 Nov;206(9):1386-93. doi: 10.1093/infdis/jis514. Epub 2012 Aug 20.
5
Comparison of norovirus RNA levels in outbreak-related oysters with background environmental levels.比较暴发相关牡蛎中的诺如病毒 RNA 水平与背景环境水平。
J Food Prot. 2012 Feb;75(2):389-93. doi: 10.4315/0362-028X.JFP-11-360.
6
Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus.血清血凝抑制活性与感染诺沃克病毒的人预防胃肠炎的能力相关。
Clin Vaccine Immunol. 2012 Feb;19(2):284-7. doi: 10.1128/CVI.05592-11. Epub 2011 Dec 21.
7
Norovirus vaccine against experimental human Norwalk Virus illness.诺如病毒疫苗对实验性人类诺如病毒病的作用。
N Engl J Med. 2011 Dec 8;365(23):2178-87. doi: 10.1056/NEJMoa1101245.
8
Serological responses to experimental Norwalk virus infection measured using a quantitative duplex time-resolved fluorescence immunoassay.使用定量双工时间分辨荧光免疫测定法测量对实验性诺如病毒感染的血清学反应。
Clin Vaccine Immunol. 2011 Jul;18(7):1187-90. doi: 10.1128/CVI.00039-11. Epub 2011 May 18.
9
Detection of norovirus infection in the hospital setting using vomit samples.使用呕吐物样本检测医院环境中的诺如病毒感染。
J Clin Virol. 2011 May;51(1):86-7. doi: 10.1016/j.jcv.2011.02.007. Epub 2011 Mar 3.
10
Serological correlate of protection against norovirus-induced gastroenteritis.诺如病毒胃肠炎血清保护相关性。
J Infect Dis. 2010 Oct 15;202(8):1212-8. doi: 10.1086/656364.